Wall Street Zen Upgrades Penumbra (NYSE:PEN) to Buy

22 Dec 2025, 01:58 by Amy Steele · The Cerbat Gem

Penumbra (NYSE:PEN – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

PEN has been the subject of several other reports. Citigroup raised shares of Penumbra from a “neutral” rating to a “buy” rating and increased their price target for the company from $285.00 to $350.00 in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research note on Monday, December 15th. BTIG Research reissued a “buy” rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, October 27th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $355.00 price target on shares of Penumbra in a report on Wednesday. Finally, Truist Financial upped their price target on Penumbra from $312.00 to $370.00 and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $333.47.

Get Our Latest Stock Analysis on Penumbra

Penumbra Trading Up 0.2%

Shares of NYSE:PEN opened at $315.98 on Friday. Penumbra has a 12-month low of $221.26 and a 12-month high of $320.00. The business’s fifty day simple moving average is $274.47 and its 200-day simple moving average is $260.91. The company has a market capitalization of $12.37 billion, a PE ratio of 75.59, a P/E/G ratio of 2.61 and a beta of 0.66. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm had revenue of $354.69 million during the quarter, compared to analysts’ expectations of $340.77 million. During the same period in the prior year, the business posted $0.85 EPS. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. As a group, equities research analysts predict that Penumbra will post 3.67 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In related news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $292.98, for a total value of $29,298.00. Following the completion of the transaction, the director owned 8,416 shares in the company, valued at $2,465,719.68. This trade represents a 1.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Arani Bose sold 15,000 shares of Penumbra stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $308.82, for a total value of $4,632,300.00. Following the sale, the director directly owned 258,462 shares of the company’s stock, valued at approximately $79,818,234.84. This represents a 5.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 34,744 shares of company stock worth $10,387,474. Company insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Institutional investors and hedge funds have recently modified their holdings of the company. Mather Group LLC. purchased a new stake in Penumbra in the third quarter valued at approximately $25,000. Newbridge Financial Services Group Inc. acquired a new stake in Penumbra during the 2nd quarter valued at approximately $30,000. Rothschild Investment LLC acquired a new stake in Penumbra during the 3rd quarter valued at approximately $40,000. Parkside Financial Bank & Trust boosted its holdings in shares of Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after acquiring an additional 66 shares during the last quarter. Finally, Covestor Ltd increased its stake in shares of Penumbra by 53.0% in the third quarter. Covestor Ltd now owns 179 shares of the company’s stock worth $46,000 after acquiring an additional 62 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Key Headlines Impacting Penumbra

Here are the key news stories impacting Penumbra this week:

Positive Sentiment: JPMorgan upgraded PEN from Neutral to Overweight and bumped its target to $370 (from $275), signaling stronger conviction in Penumbra’s growth trajectory and implying meaningful upside vs. the current share level. JP Morgan Upgrades Penumbra (PEN)
Positive Sentiment: Truist raised its price target to $370 from $312 and reiterated a Buy, reinforcing the bullish view and matching JPMorgan’s $370 target that implies roughly mid‑teens upside from current levels. Penumbra upgraded to overweight from neutral at JPMorgan
Positive Sentiment: Additional price-target lifts from RBC (to $355 from $325) and Canaccord (to $359 from $355) add to the consensus upward drift in sell‑side expectations. These moves tighten the buy-side narrative around recurring CAVT adoption and international growth. Penumbra price target raised to $359 from $355 at Canaccord Penumbra price target raised to $355 from $325 at RBC Capital
Positive Sentiment: Needham reiterated a Buy rating, supporting the positive analyst tone and reducing near‑term downside risk from the sell‑side. Needham maintains Penumbra (PEN) buy recommendation
Positive Sentiment: Clinical/outcomes coverage: a published evaluation of Penumbra’s CAVT in intermediate‑risk pulmonary embolism (PE) patients highlights outcomes and resource‑utilization benefits—supportive evidence for broader clinical adoption and reimbursement discussions. Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients
Neutral Sentiment: Media/awareness: Bloomberg’s healthcare segment highlighted Penumbra’s efforts to expand CAVT awareness—positive for long‑term market penetration but more of a brand/voice play than an immediate revenue driver. Vanguards of Health Care: Penumbra Expands CAVT Awareness

About Penumbra

(Get Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.